August 20, 2024
1 min read
Save
Visiox Pharmaceuticals merges with Ocuvex Therapeutics
Visiox Pharmaceuticals has entered into a definitive merger agreement with Ocuvex Therapeutics, according to a press release.
The company will operate under the Ocuvex name and include Visiox’s products, including Omlonti (omidenepag isopropyl ophthalmic solution), PDP-716 (brimonidine 0.35%) and SDN-037 (difluprednate 0.04%).
“The combination of Visiox and Ocuvex makes for a perfect match,” Ryan S. Bleeks, CEO of Visiox, said in the release. “We have reached significant milestones with our products, and Ocuvex is in a great position to take these advancements forward and bring them to market faster and emerge as a future leader in eye care.”
Published by:
Read more about